Pharma News
Pamplona investment group buys majority share in Alvolgen
Specialist investment manager Pamplona Capital Management (Pamplona) announced on 2 April 2014 that it had acquired a majority stake in US generics company Alvogen, one of the fastest growing generics companies in the pharmaceutical industry.
Actavis to acquire generics from Akorn
US generics major Actavis announced on 17 April 2014 that it had made a deal with Akorn and Hi-Tech Pharmacal (Hi-Tech) to buy five of their products.
UK court invalidates Herceptin patents
A High Court in the UK has overturned two key patents on Roche’s breast cancer blockbuster Herceptin (trastuzumab).
Sun Pharma to acquire Ranbaxy creating 5th largest generics firm
India-based Sun Pharmaceutical (Sun Pharma) announced on 6 April 2014 that the company had agreed to acquire rival generics maker Ranbaxy Laboratories (Ranbaxy) in an all-stock deal worth US$3.2 billion.
Actavis buys Thai generics company
US generics major Actavis has acquired Silom Medical Company, a privately held generics firm focused on developing and marketing therapies in Thailand, for around US$100 million in cash.
US FTC hopes to collect US$1 billion from pay-for-delay settlement
The US Federal Trade Commission (FTC) is looking to collect more than US$1 billion from a settlement with pharmaceutical companies it has sued for their part in what the FTC terms ‘pay-for-delay’ deals.
Anticompetitive practices come under scrutiny in Australia
The Australian Competition and Consumer Commission (ACCC) has started proceedings in the Federal Court against Pfizer Australia (Pfizer) alleging that offers made by Pfizer to pharmacies before the expiry of the patents for its blockbuster cholesterol-lowering drug Liptor (atorvastatin) were anticompetitive.
Actavis to acquire specialty drugmaker Forest Labs
US-based generic drugmaker Actavis is set to grow even bigger, with the acquisition of US-based Forest Laboratories (Forest Labs), according to an announcement by the companies on 18 February 2014.
Actavis sells interest in China
US generic drugmaker Actavis has sold its interest in its Chinese subsidiary based in Foshan, Guangdong, to Zhejiang Chiral Medicine Chemicals. Actavis, the second biggest generic drugmaker by market capitalization, intends to continue further commercial operations in China in collaboration with its preferred business partners.
Aurobindo to acquire seven generics businesses from Actavis
US generics maker Actavis and Indian generics maker Aurobindo Pharma (Aurobindo) announced on 17 January 2014 the signing of an offer for Aurobindo to acquire generics commercial operations in seven markets in Western Europe from Actavis.
